Results 291 to 300 of about 788,607 (367)

Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach. [PDF]

Cardiovasc Drugs Ther
Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Mikus G, Meid AD, Haefeli WE, Blank A.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?

HIP International, 2020
Introduction: Debate over the ideal agent for venous thromboembolism (VTE) prophylaxis after total hip arthroplasty (THA) has led to changes in prescribing trends of commonly used agents. We investigate variation in utilisation and the differences in VTE
Abiram Bala, M. Murasko, D. Burk, J. Huddleston, S. Goodman, W. Maloney, D. Amanatullah   +6 more
semanticscholar   +1 more source

Factor Xa inhibitors

Expert Opinion on Therapeutic Patents, 1999
The invention provides compounds which specifically inhibit factor Xa activity. The compounds consist of the structure X1 -YIR-X2, wherein X1 is H, acyl, alkyl, acylalkyl, arylalkyl or one or more amino acids, and X2 is a modified C-terminal group, one or more carboxy-protecting groups or one or more amino acids or other substituent, and Y, I and R are
Pavel Safar, Peter Strop, Alena Stierandova, Fahad Al-Obeidi, Michal Lebl, James A. Ostrem, Armin Walser   +6 more
openaire   +2 more sources

A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis

The Annals of Pharmacotherapy, 2020
Background: Clinical practice guidelines recommend that cerebral venous thrombosis (CVT) be managed with long-term anticoagulant therapy using warfarin or low-molecular-weight heparin (LMWH) for 3 to 12 months.
Marissa Z Powell, Kathryn Tremolet de Villers, K. Schwarz, D. Case, T. Trujillo   +4 more
semanticscholar   +1 more source

Inhibitors of Factor Xa [PDF]

, 1999
Thrombin occupies a central position in thrombus formation and recently has been a target for the development of anticoagulant agents. As is well known, blood coagulation operates as a cascade or multiple enzymatic amplification process. In the classical intrinsic pathway, factor (f) IXa in the presence of fVIIIa, Ca2+ and phospholipid converts fX to ...
S. Kunitada, T. Hara, T. Nagahara
openaire   +1 more source

Anthranilamide inhibitors of factor Xa

Bioorganic & Medicinal Chemistry Letters, 2007
SAR about the B-ring of a series of N(2)-aroyl anthranilamide factor Xa (fXa) inhibitors is described. B-ring o-aminoalkylether and B-ring p-amine probes of the S1' and S4 sites, respectively, afforded picomolar fXa inhibitors that performed well in in vitro anticoagulation assays.
Jeffry Bernard Franciskovich, Angela Lynn Marquart, Ying K. Yee, Gerald F. Smith, Valentine J. Klimkowski, Larry L. Froelich, Kyle Ja, Jennifer M. Tinsley, John A. Buben, David Mendel, Philip Parker Waid, Trelia J. Craft, David K. Herron, Anne Louise Tebbe, John Joseph Masters, Sajan Joseph, Andrew Michael Ratz, Leonard C. Weir, Theodore Goodson, Michael Robert Wiley, Richard D. Towner   +20 more
openaire   +3 more sources

Rivaroxaban: An Oral Factor Xa Inhibitor

Clinical Therapeutics, 2013
Currently available anticoagulants utilized for venous thromboembolism (VTE) treatment and prevention and stroke prevention in patients with atrial fibrillation (AF) have proven effectiveness but are not optimally utilized because of barriers such as the need for subcutaneous administration and requisite routine laboratory monitoring.
Valerie S. Ganetsky, Tyan Thomas, Sarah A. Spinler   +2 more
openaire   +3 more sources

Heterogeneity of Synthetic Factor Xa Inhibitors

Current Pharmaceutical Design, 2005
Heparins and vitamin K antagonists are the landmarks of antithrombotic treatment. Both of them were discovered by serendipity; they are multi-targeted drugs and share several limitations. New molecules have been designed in order to be both more selective concerning their biological target and more homogeneous in their biochemical structure aiming at ...
Grigoris T. Gerotziafas, Meyer Michel Samama   +1 more
openaire   +3 more sources